Table.
Vaccines currently being administered in North America and Europe
| Vaccine name | Type | Dosage | Efficacy rate after full dose | Contraindication |
|---|---|---|---|---|
| Pfizer-BioNTech | mRNA | 2 doses separated by 3 wk | 95.0% (95% CI 90.3%–97.6%)4 | Polyethylene glycol allergy |
| Moderna | mRNA | 2 doses separated by 4 wk | 94.1% (95% CI 89.3%–96.8%)4 | Polyethylene glycol allergy |
| Janssen (Johnson & Johnson) | Adenoviral vector | 1 dose | 66.3% (95% CI 59.9%–71.8%)4 | Polysorbate allergy |
| AstraZenecaa | Adenoviral vector | 2 doses separated by 12 wk | 81.2% (95% CI 60.3%–91.2%)5 | Polysorbate allergy |
a
Not authorized for use in the United States.